Diagonal Bio's CEO Karin Wehlin increases ownership

"I had a top underwriting commitment in the recently conducted rights issue and since we had such a successful outcome with an oversubscription of the issue, I was not allocated any units besides my pro-rata part. Based on this and of course based on my strong belief in the team at Diagonal Bio and the future of the Company, I decided to purchase shares in the market to increase my holdings." - Karin Wehlin, CEO of Diagonal Bio AB (publ)


For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO

Phone: +46 703 052488

E-mail: kw@diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

E-mail: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.

Datum 2025-02-12, kl 15:45
Källa Cision
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet